表 1.

入组患者的一般基线特征

Demographic and baseline characteristics

Items	Atezolizumab (n=100)	Atezolizumab+gemcitabine+cisplatin (n=20)
CRC, colorectal cancer; UC, urothelial cancer; PK, pharmacokinetics; PD-L1, programmed death-ligand 1; EBV, Epstein-Barr virus; MSI-H, microsatellite instability-high; BTC, biliary tract carcinoma; NET, neuroendocrine tumor; ECOG, Eastern Cooperative Oncology Group; IC, immune cells; TC, tumor cells; NA, not applicable. Other abbreviations as in Figure 1. a, PD-L1+ status is defined as IC or TC≥1%; b, PD-L1 IC score at baseline: IC < 1% (IC0), 1% < IC < 5% (IC1), 5% < IC < 10% (IC2), IC≥10% (IC3); c, PD-L1 TC score at baseline: TC < 1% (TC0), 1% < TC < 5% (TC1), 5% < TC < 50% (TC2), TC≥50% (TC3).
Age/years, median (range)	55.0 (19.0-77.0)	60.0 (38.0-77.0)
Age < 65 years, n(%)	81 (81.0)	14 (70.0)
Male, n(%)	80 (80.0)	18 (90.0)
Weight/kg, Median (Range)	60.0 (33.0-96.0)	64.5 (47.0-94.0)
Study cohort
EC (PD-L1+/PD-L1-), n	20 (10/10)	NA
GC (PD-L1+/PD-L1-/EBV+/MSI-H), n	20 (6/14/10/5)	NA
HCC (PD-L1+/PD-L1-), n	20 (8/12)	NA
NPC (PD-L1+/PD-L1-), n	20 (15/5)	NA
NSCLC (PD-L1+/PD-L1-), n	NA	20 (13/7)
PK (NSCLC/CRC/GC/UC/EC/HCC/BTC/NET)，n	20 (7/4/4/1/1/1/1/1)	NA
ECOG performance score, n(%)
0	21 (21.0)	0
1	79 (79.0)	20 (100.0)
PD-L1+a, n(%)	42 (42.0)	13 (65.0)
PD-L1 IC scoreb, n(%)
IC0	63 (63.0)	10 (50.0)
IC1	26 (26.0)	6 (30.0)
IC2	3 (3.0)	2 (10.0)
IC3	5 (5.0)	1 (5.0)
Unknown	3 (3.0)	1 (5.0)
PD-L1 TC scorec, n(%)
TC0	81 (81.0)	13 (65.0)
TC1	5 (5.0)	1 (5.0)
TC2	10 (10.0)	1 (5.0)
TC3	1 (1.0)	4 (20.0)
Unknown	3 (3.0)	1 (5.0)
Tobacco use, n(%)
Current	6 (6.0)	0
Previous	40 (40.0)	14 (70.0)
Never	54 (54.0)	6 (30.0)
Alcohol use, n(%)
Current	5 (5.0)	0
Previous	32 (32.0)	11 (55.0)
Never	63 (63.0)	9 (45.0)
Prior radiotherapy, n(%)	43 (43.0)	4 (20.0)
MSI-H (all cancer types), n(%)	9 (9.0)	0
Prior therapy for recurrent/metastatic disease, n(%)	91 (91.0)	1 (5.0)